Tong Xiang, Li Zhenzhen, Fu Xiaowei, Zhou Kai, Wu Yao, Zhang Yonggang, Fan Hong
West China School of Medicine/West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
Tumour Biol. 2014 Sep;35(9):8707-13. doi: 10.1007/s13277-014-2040-8. Epub 2014 May 29.
The CD14-260C/T polymorphism has been implicated to be in association with malignant tumor. However, a number of studies have reported inconclusive results. The aim of this study was to investigate the relationship of CD14-260C/T polymorphism and malignant tumor risk by meta-analysis. A search was performed in PubMed, Embase, the Chinese Journals Full-text Database (CNKI), and Wanfang databases up to August 2013. Odds ratio (OR) and 95 % confidence interval (95 % CI) were used to assess the association. Statistical analysis was calculated by STATA 11.0 software. The polymorphism was identified from 11 articles (12 case-control studies), involving 2,660 cases and 2,943 controls. Overall, no significant association between CD14-260C/T polymorphism and malignant tumor risk was found in the dominant model (TT + TC vs. CC: OR = 0.86, 95 % CI = 0.67-1.11). In the subgroup analysis by malignant tumor types, we found that the heterozygote model (TC vs. CC) might reduce the risk of malignant tumor, especially hematological malignance and prostate cancer (OR = 0.67, 95 % CI = 0.47-0.95), but not associated with gastrointestinal cancer susceptibility. In the subgroup analysis by ethnicity, no significant associations were found among different ethnicities. The study suggested that CD14-260C/T polymorphism might be a protective factor for hematological malignance and prostate tumor susceptibility but not an independent risk factor for gastrointestinal cancer susceptibility. To further evaluate the association between the polymorphism and malignant tumor susceptibility, more studies involving thousands of patients are required.
CD14 - 260C/T基因多态性被认为与恶性肿瘤有关。然而，许多研究报告的结果并不确定。本研究的目的是通过荟萃分析探讨CD14 - 260C/T基因多态性与恶性肿瘤风险之间的关系。截至2013年8月，我们在PubMed、Embase、中国期刊全文数据库（CNKI）和万方数据库中进行了检索。采用比值比（OR）和95%置信区间（95%CI）来评估关联性。使用STATA 11.0软件进行统计分析。从11篇文章（12项病例对照研究）中鉴定出该基因多态性，涉及2660例病例和2943例对照。总体而言，在显性模型中（TT + TC与CC相比：OR = 0.86，95%CI = 0.67 - 1.11），未发现CD14 - 260C/T基因多态性与恶性肿瘤风险之间存在显著关联。在按恶性肿瘤类型进行的亚组分析中，我们发现杂合子模型（TC与CC相比）可能会降低恶性肿瘤的风险，尤其是血液系统恶性肿瘤和前列腺癌（OR = 0.67，95%CI = 0.47 - 0.95），但与胃肠道癌易感性无关。在按种族进行的亚组分析中，不同种族之间未发现显著关联。该研究表明，CD14 - 260C/T基因多态性可能是血液系统恶性肿瘤和前列腺肿瘤易感性的保护因素，但不是胃肠道癌易感性的独立危险因素。为了进一步评估该基因多态性与恶性肿瘤易感性之间的关联，需要更多涉及数千名患者的研究。
